Sylus Co., Ltd., established in April 2019, is a research joint venture by Samyoung Unitech Co., Ltd. and Daegu Gyeongbuk Institute of Science and Technology for the development of new peptides.Starting with the development of anemia treatment drugs, we are focusing on the development of various disease treatments, including neurodegenerative diseases.
Samyoung Unitech, the parent company of Sylus, is a radiopharmaceutical manufacturing company and the first company to receive KGMP certification for radiopharmaceuticals.
Sylus was incorporated in April 2019 and is headquartered in the Jeonbuk Special Economic Zone.
We are developing new peptide drug treatments for a healthy society and striving to become a global biotech company.
- Drug Discovery
- IND - Enabling
- Phase 1
- Phase 2
Sylus strives to successfully develop new drug treatments for a healthy society.
We value our commitment and to the highest professional standard in the industry and a persistent attitude to problem-solving.
Inquiry : email@example.com